Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: A meta-analysis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 182, Issue , 2014, Pages 194-201

  Allen, Rebecca E ^a   Rogozinska, Ewelina ^b   Cleverly, Kirsty ^a   Aquilina, Joseph ^a   Thangaratinam, S ^a,b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biomarkers; First trimester; Prediction; Preeclampsia; Pregnancy

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; ENDOGLIN; INHIBIN A; PADGEM PROTEIN; PENTRAXIN; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; C REACTIVE PROTEIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; INHIBIN; LEUKOCYTE ANTIGEN; PENTRAXIN 3; PLACENTAL GROWTH FACTOR; SERUM AMYLOID P;

ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; MATERNAL BLOOD; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; GESTATIONAL AGE; META ANALYSIS; METABOLISM; PREGNANCY;

ANTIGENS, CD; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GESTATIONAL AGE; HUMANS; INHIBINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RECEPTORS, CELL SURFACE; SERUM AMYLOID P-COMPONENT;

EID: 84920649518     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2014.09.027     Document Type: Article

References (51)

1. E. Bujold, S. Roberge, and Y. Lacasse Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis Obstet Gynecol 116 2 Pt 1 2010 402 414
2. National Institute of Clinical Excellence National Institute of Clinical Excellence guidelines hypertension in pregnancy 2010 http://publications.nice.org.uk/hypertension-in-pregnancy-cg107
3. A. Conde-Agudelo, J. Villar, and M. Lindheimer World Health Organization systematic review of screening tests for preeclampsia Obstet Gynecol 104 6 2004 1367 1391
4. Y. Giguere, M. Charland, and E. Bujold Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review Clin Chem 56 3 2010 361 375
5. R. North, L. McCowan, and G. Dekker Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort BMJ 342 2011 d1875
6. W. Plasencia, N. Maiz, S. Bonino, C. Kaihura, and K.H. Nicolaides Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia Ultrasound Obstet Gynecol 30 5 2007 742 749
7. K. Spencer, C.K. Yu, N.J. Cowans, C. Otigbah, and K.H. Nicolaides Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler Prenat Diagn 25 10 2005 949 953
8. S. Saleh, A. Antoniou, K. Harrington, and J. Aquilina Second trimester maternal serum cystatin C levels in preeclamptic and normotensive pregnancies: a small case-control study Hypertens Pregnancy 29 1 2010 112 119
9. S. Bower, S. Bewley, and S. Campbell Improved prediction of preeclampsia by two-stage screening of uterine arteries using the early diastolic notch and color Doppler imaging Obstet Gynecol 82 1 1993 78 83
10. K. Harrington, D. Cooper, C. Lees, K. Hecher, and S. Campbell Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby Ultrasound Obstet Gynecol 7 3 1996 182 188
11. J. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions: Cochrane collaboration 2008
12. G. Wells, B. Shea, and D. O'Connell The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analysis 2011 Available at http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
13. S. Chinn A simple method for converting an odds ratio to effect size for use in meta-analysis Stat Med 19 22 2000 3127 3131
14. A. Abdelaziz, M.A. Maher, T.M. Sayyed, M.F. Bazeed, and N.S. Mohamed Early pregnancy screening for hypertensive disorders in women without a-priori high risk Ultrasound Obstetr Gynecol 40 4 2012 398 405
15. R. Akolekar, E. Zaragoza, L.C. Poon, S. Pepes, and K.H. Nicolaides Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia Ultrasound Obstetr Gynecol 32 6 2008 732 739
16. R. Akolekar, R. Minekawa, A. Veduta, X.C. Romero, and K.H. Nicolaides Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy Prenat Diagn 29 8 2009 753 760
17. V.L. Bills, J. Varet, A. Millar, S.J. Harper, P.W. Soothill, and D.O. Bates Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia Clin Sci 116 3 2009 265 272
18. P.M. Bosio, S. Cannon, P.J. McKenna, C. O'Herlihy, R. Conroy, and H. Brady Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia BJOG 108 7 2001 709 715 (An International Journal of Obstetrics & Gynaecology)
19. I. Cetin, V. Cozzi, and A.T. Papageorghiou First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction Acta Obstetr Gynecol Scand 88 7 2009 846 849
20. L. Dugoff, J.C. Hobbins, and F.D. Malone First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial) Am J Obstetr Gynecol 191 4 2004 1446 1451
21. M.N. El-Gharib, and M. Morad Maternal serum inhibin-A for predicting preeclampsia J Matern Fetal Neonat Med 24 4 2011 595 599
22. W.S. El Sherbiny, A. Soliman, and A.S. Nasr Placental protein 13 as an early predictor in Egyptian patients with preeclampsia, correlation to risk, and association with outcome J Invest Med 60 5 2012 818 822
23. K.R. Goetzinger, A. Singla, S. Gerkowicz, J.M. Dicke, D.L. Gray, and A.O. Odibo Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG Prenat Diagn 30 12-13 2010 1138 1142
24. R. Madazli, B. Bulut, A. Tuten, B. Aydin, G. Demirayak, and M. Kucur First-trimester maternal serum metastin, placental growth factor and chitotriosidase levels in pre-eclampsia Eur J Obstetr, Gynecol, Reprod Biol 164 2 2012 146 149
25. A.O. Odibo, Y. Zhong, and K.R. Goetzinger First-trimester placental protein 13,PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia Placenta 32 8 2011 598 602
26. L.C. Poon, N. Maiz, C. Valencia, W. Plasencia, and K.H. Nicolaides First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia Ultrasound Obstetr Gynecol 33 1 2009 23 33
27. S. Rana, S.A. Karumanchi, and R.J. Levine Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia Hypertension 50 1 2007 137 142
28. L.J. Salomon, C. Benattar, and F. Audibert Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy Am J Obstetr Gynecol 189 6 2003 1517 1522
29. F.J. Schneuer, N. Nassar, and A.Z. Khambalia First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review Placenta 33 9 2012 735 740
30. Z. Saruhan, M. Ozekinci, M. Simsek, and I. Mendilcioglu Association of first trimester low PAPP-A levels with adverse pregnancy outcomes Clin Exp Obstetr Gynecol 39 2 2012 225 228
31. R. Thadhani, W.P. Mutter, and M. Wolf First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia J Clin Endocrinol Metab 89 2 2004 770 775
32. E.J. Wortelboer, M.P. Koster, H.S. Cuckle, P.H. Stoutenbeek, P.C. Schielen, and G.H. Visser First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia BJOG 117 11 2010 1384 1389 (An International Journal of Obstetrics & Gynaecology)
33. Y. Zhong, M. Tuuli, and A.O. Odibo First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction Prenat Diagn 30 4 2010 293 308
34. Y. Yaron, Y. Ochshorn, S. Heifetz, O. Lehavi, Y. Sapir, and A. Orr-Urtreger First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome Fetal Diagn Ther 17 6 2002 352 356
35. N.J. Sebire, L. Roberts, P. Noble, E. Wallace, and K.H. Nicolaides Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia BJOG 107 6 2000 795 797 (An International Journal of Obstetrics & Gynaecology)
36. I. Chafetz, I. Kuhnreich, and M. Sammar First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction Am J Obstet Gynecol 197 1 2007 35e1 35e7
37. A.M. Lynch, J.R. Murphy, and R.S. Gibbs The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia BJOG 117 4 2010 456 462 (An International Journal of Obstetrics & Gynaecology)
38. L. Vatten, A. Eskild, T.I.L. Nilsen, S. Jeansson, P.A. Jenum, and A.C. Staff Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia Am J Obstet Gynecol 196 3 2007 239.e1 239.e6
39. M.U. Baumann, N.A. Bersinger, M.G. Mohaupt, L. Raio, S. Gerber, and D.V. Surbek First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia Am J Obstetr Gynecol 199 3 2008 266.e1 266.e6
40. T. Chaiworapongsa, R. Romero, and Y.M. Kim Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia J Matern Fetal Neonatal Med 17 1 2005 3 18
41. M. Noori, A.E. Donald, A. Angelakopoulou, A.D. Hingorani, and D.J. Williams Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension Circulation 122 5 2010 478 487
42. V. Radoi, and L. Bohiltea Pregnancy associated plasma protein A and pregnancy outcomes Gineco 5 1 2009
43. S. Kuc, E.J. Wortelboer, B.B. van Rijn, A. Franx, G.H. Visser, and P.C. Schielen Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review Obstetr Gynecol Surv 66 4 2011 225 239
44. A.C. Pedrosa, and A. Matias Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers J Perinat Med 39 6 2011 619 635
45. C.E. Kleinrouweler, M.M. Wiegerinck, and C. Ris-Stalpers Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis Br J Obstet Gynaecol 119 7 2012 778 787
46. R. Pijnenborg, J. Anthony, and D.A. Davey Placental bed spiral arteries in the hypertensive disorders of pregnancy Br J Obstet Gynaecol 98 7 1991 648 655
47. T.Y. Khong, F. De Wolf, W.B. Robertson, and I. Brosens Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants Br J Obstet Gynaecol 93 10 1986 1049 1059
48. P. Villa, H.E. Maki, A. Raikkonen, K. Pesonnen, A.-K. Taipale, P. Kajantie, and E.H. Laivuori Vasoactive agents for the prediction of early and late onset preeclampsia in a high risk cohort BMC Pregnancy Childbirth 13 2013
49. S. Grill, C. Rusterholz, and R. Zanetti-Dallenbach Potential markers of preeclampsia - a review Reprod Biol Endocrinol 7 70 2009
50. R. Romero, N.J. Espinosa, and J.D. Todem A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J Maternal, Fetal Neonat Med 21 2008 9 23
51. L. Duley, D.J. Henderson-Smart, M. Knight, and A.H. Shennan Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Evid-Based Med 10 2 2005